Financial Personal
Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster
First participant dosed in the Covigenix VAX-002 Phase 1/2 Study to Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 EDMONTON, Alberta & SAN DIEGO — Entos® Pharmaceuticals ( Entos or the C
EDMONTON, Alberta & SAN DIEGO -- Entos® Pharmaceuticals ( Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix™ PLV™ nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced the first participant has been dosed in the phase 1/2 clinical trial ( NCT06436911) evaluating Covigenix VAX-002 as a COVID-19 booster vaccine. Read More
Related
Share this page
Guest Posts by Easy BranchesGet Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.
